Avandia Panel Wants Another Trial: Pipe Dream Or Post-market Benchmark?
Executive Summary
Designed with complex, multi-variate statistics, an observational trial could determine the CV risk of rosiglitazone compared to other diabetes drugs, an advisory committee member suggests during the latest assessment of Avandia.
You may also be interested in...
PharmaRoth Looks Abroad With Type 2 Diabetes Product After NDI Notification Decision
FDA decides Sucanon is an investigational new drug, not a dietary ingredient, in response to PharmaRoth Labs’ NDI notification. The firm expected to sell Sucanon as a consumer health supplement via infomercials with no claims, but faces substantially higher costs on the IND pathway to market.
PharmaRoth Looks Abroad With Type 2 Diabetes Product After NDI Notification Decision
FDA decides Sucanon is an investigational new drug, not a dietary ingredient, in response to PharmaRoth Labs’ NDI notification. The firm expected to sell Sucanon as a consumer health supplement via infomercials with no claims, but faces substantially higher costs on the IND pathway to market.
PharmaRoth Looks Abroad With Type 2 Diabetes Product After NDI Notification Decision
FDA decides Sucanon is an investigational new drug, not a dietary ingredient, in response to PharmaRoth Labs’ NDI notification. The firm expected to sell Sucanon as a consumer health supplement via infomercials with no claims, but faces substantially higher costs on the IND pathway to market.